CellSeed Inc. belongs to the Health Care sector. Filings by its managers are published through EDINET (Japan FSA). Over the twelve months to 18 October 2026, 19 filings were filed, from 1 insider.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of CellSeed Inc. for at least a year. Between a trade and the moment it shows up on EDINET (Japan FSA), the median delay is 7 days. That lag is the time during which only the insider knows about the trade.
With 19 filings in twelve months, the company is more active than the median of 3 filings across the 3,427 companies we follow on the same exchange.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by EDINET (Japan FSA). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 74 declarations
株式会社セルシード is a Japanese company operating in the healthcare and pharmaceutical sector. It focuses on the development of stem cell technologies and regenerative therapies.
Purchases our model currently ranks for the recommendations list.
All recommendations